Avid Bioservices Inc (CDMO)

[entdoc]

ftm, I am a clinician who also combs the peer-reviewed literature on a daily basis, the poster presentations abstracted at ASCO are excellent: packed with choice information which arrests one's interest and, like you, leaves all in tune here wanting more. I say, "Excellent work PPHM!" This entire ASCO should be dedicated to Phil Thorpe, PhD, PPHM's visionary and now parted pharmacological genius. As just mentioned, the NSCLC ECOG figures are mind-boggling. To get an idea of the enormous difference between Ecog 2 and Ecog 3 patients, one need only review this website. Amazing. "abstractinghttp://ecog.dfci.harvard.edu/general/perf_stat.html.
The best thing about BAVI is it is so far from being a dead-end treatment soon to be supplanted by the next generation of anti-cancer agents. Bavi's stimulation of the immune system in cancer is only scratching the surface of its vast potential...in imaging (Bavi uptake studies), and as a fully humanized anti-PS MAB capable of packing a load in its second arm...A missile that can attach to exteriorized -PS with one arm, and lob an anti-neoplastic small molecule with the other.
great posts lately! And congratulations to everyone involved in this incredible effort at ASCO this year! Believe me, PPHM will be noticed bigtime.